ADC Therapeutics SA Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes
ADC Therapeutics SA (ADCT) reported Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes of -$16.07 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges · last filed 2023-11-07
- ADC Therapeutics SA increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2023-03-31 was -$15.98M.
- ADC Therapeutics SA increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2022-03-31 was -$35.59M.
- ADC Therapeutics SA increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2021-03-31 was -$56.10M.
- ADC Therapeutics SA increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2020-03-31 was -$32.88M.
| Period end | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 3 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 6 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 9 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$16.07M 6-K · filed 2023-11-07 | |||
| 2023-06-30 | $20.92M 6-K · filed 2023-08-08 | |||
| 2023-03-31 | -$15.98M 6-K · filed 2023-05-09 | |||
| 2022-12-31 | -$139.90M 20-F · filed 2023-03-15 | |||
| 2022-09-30 | -$85.23M 6-K · filed 2023-11-07 | |||
| 2022-06-30 | -$89.54M 6-K · filed 2023-08-08 | |||
| 2022-03-31 | -$35.59M 6-K · filed 2023-05-09 | |||
| 2021-12-31 | $27.34M 20-F · filed 2023-03-15 | |||
| 2021-09-30 | $91.02M 6-K · filed 2022-11-08 | |||
| 2021-06-30 | -$67.36M 6-K · filed 2022-08-09 | |||
| 2021-03-31 | -$56.10M 6-K · filed 2022-05-09 | |||
| 2020-12-31 | $323.41M 20-F · filed 2023-03-15 | |||
| 2020-09-30 | $378.77M 6-K · filed 2021-11-02 | |||
| 2020-06-30 | $233.17M 6-K · filed 2021-08-03 | |||
| 2020-03-31 | -$32.88M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | -$23.32M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | -$123.89M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |